
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3990781/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Otopathogen interactions in the nasopharynx of children, and the predictive value of nasopharyngeal aspirate culture for the aetiology of upper respiratory infections. Journal of Paediatrics and Child Health, 2021, 57, 1016-1022.	0.4	2
2	Vaccination against respiratory <i>Pseudomonas aeruginosa</i> infection. Human Vaccines and Immunotherapeutics, 2015, 11, 14-20.	1.4	62
3	The roles of epithelial cell contact, respiratory bacterial interactions and phosphorylcholine in promoting biofilm formation by Streptococcus pneumoniae and nontypeable Haemophilus influenzae. Microbes and Infection, 2014, 16, 640-647.	1.0	8
4	Mucosal and systemic antibody responses to potentialPseudomonas aeruginosavaccine protein antigens in young children with cystic fibrosis following colonization and infection. Human Vaccines and Immunotherapeutics, 2013, 9, 506-514.	1.4	24
5	Epitope-specific immune recognition of the nontypeableHaemophilus influenzaeouter membrane protein 26. Human Vaccines and Immunotherapeutics, 2013, 9, 625-635.	1.4	5
6	Panel 5. Otolaryngology - Head and Neck Surgery, 2013, 148, E64-E89.	1.1	15
7	A Quadruple Knockout of lasIR and rhIIR of Pseudomonas aeruginosa PAO1 That Retains Wild-Type Twitching Motility Has Equivalent Infectivity and Persistence to PAO1 in a Mouse Model of Lung Infection. PLoS ONE, 2013, 8, e60973.	1.1	15
8	The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media. Current Immunology Reviews, 2013, 9, 57-71.	1.2	1
9	Airway Bacterial Interactions and Impact on Host Immune Responses. Advances in Oto-Rhino-Laryngology, 2011, 72, 116-120.	1.6	8
10	Mucosal Immunization with the Moraxella Catarrhalis Porin M35 Induces Enhanced Bacterial Clearance from the Lung: A Possible Role for Opsonophagocytosis. Frontiers in Immunology, 2011, 2, 13.	2.2	8
11	Mechanisms of Bacterial Resistance to Antibiotics in Infections of COPD Patients. Current Drug Targets, 2011, 12, 521-530.	1.0	32
12	Effectiveness of engineering the nontypeable <i>Haemophilus influenzae</i> antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery. Hum Vaccin, 2011, 7, 99-107.	2.4	13
13	Developmental Profiles of Mucosal Immunity in Pre-school Children. Clinical and Developmental Immunology, 2010, 2010, 1-10.	3.3	9
14	The incidence of Streptococcus pneumoniae otitis media is affected by the polymicrobial environment particularly Moraxella catarrhalis in a mouse nasal colonisation model. Microbes and Infection, 2009, 11, 545-553.	1.0	43
15	Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection. Vaccine, 2009, 27, 3324-3330.	1.7	9
16	Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine, 2008, 26, 6221-6224.	1.7	64
17	<i>Moraxella catarrhalis</i> M35 Is a General Porin That Is Important for Growth under Nutrient-Limiting Conditions and in the Nasopharynges of Mice. Journal of Bacteriology, 2008, 190, 7994-8002.	1.0	14
18	Optimisation of Oral Immunization Through Receptor-Mediated Targeting of M Cells. Hum Vaccin, 2007. 3, 220-223.	2.4	11

#	Article	IF	CITATIONS
19	Comparison of mucosal and parenteral immunisation in two animal models of pneumococcal infection: Otitis media and acute pneumonia. Vaccine, 2007, 25, 2471-2477.	1.7	16
20	Receptor mediated targeting of M-cells. Vaccine, 2007, 25, 3204-3209.	1.7	37
21	Bacterial ghosts as adjuvant particles. Expert Review of Vaccines, 2007, 6, 241-253.	2.0	71
22	Enterocyte and M-Cell Transport of Native and Heat-Denatured Bovine Î ² -Lactoglobulin:Â Significance of Heat Denaturation. Journal of Agricultural and Food Chemistry, 2006, 54, 1500-1507.	2.4	28
23	Product ion mass spectra of amphetamine-type substances, designer analogues, and ketamine using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 2259-2264.	0.7	19
24	A comparison of atmospheric pressure chemical ionization and electrospray ionization in testing for amphetamine-type substances and ketamine using ultra-performance liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 2777-2780.	0.7	5
25	A demonstration of the use of ultra-performance liquid chromatography–mass spectrometry [UPLC/MS] in the determination of amphetamine-type substances and ketamine for forensic and toxicological analysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2006. 836. 111-115.	1.2	89
26	Microbial Pattern Recognition Receptors Mediate M-Cell Uptake of a Gram-Negative Bacterium. Infection and Immunity, 2006, 74, 625-631.	1.0	90
27	Impact of saliva collection methods on sIgA and cortisol assays and acceptability to participants. Journal of Immunological Methods, 2005, 307, 167-171.	0.6	107
28	Mucosal immunisation with novelStreptococcus pneumoniaeprotein antigens enhances bacterial clearance in an acute mouse lung infection model. FEMS Immunology and Medical Microbiology, 2005, 44, 59-67.	2.7	14
29	Characterization of a Novel Porin Protein from Moraxella catarrhalis and Identification of an Immunodominant Surface Loop. Journal of Bacteriology, 2005, 187, 6528-6535.	1.0	22
30	Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opinion on Biological Therapy, 2005, 5, 967-982.	1.4	31
31	Vaccines for otitis media: proposals for overcoming obstacles to progress. Vaccine, 2005, 23, 2696-2702.	1.7	30
32	Bacterial otitis media: a vaccine preventable disease?. Vaccine, 2005, 23, 2304-2310.	1.7	60
33	6. Vaccine. Annals of Otology, Rhinology and Laryngology, 2005, 114, 86-103.	0.6	23
34	Recent advances in otitis media. 6. Vaccine. The Annals of Otology, Rhinology & Laryngology Supplement, 2005, 194, 86-103.	3.0	13
35	Bacterial otitis media: Current vaccine development strategies. Immunology and Cell Biology, 2003, 81, 46-51.	1.0	32
36	Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts – a delivery system for the nontypeableHaemophilus influenzaeantigenOmp26. FEMS Immunology and Medical Microbiology, 2003, 37, 185-192.	2.7	27

#	Article	IF	CITATIONS
37	Immunisation with non-integral OMPs promotes pulmonary clearance ofPseudomonas aeruginosa. FEMS Immunology and Medical Microbiology, 2003, 37, 155-160.	2.7	18
38	Mucosal immunization against respiratory bacterial pathogens. Expert Review of Vaccines, 2003, 2, 551-560.	2.0	18
39	Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens To Induce Clearance of Nontypeable Haemophilus influenzae from the Rat Middle Ear and Lungs as Well as from the Chinchilla Middle Ear and Nasopharynx. Infection and Immunity, 2003, 71, 4691-4699.	1.0	55
40	A Vaccine for Nontypable Haemophilus influenzae. , 2003, , 244-259.		1
41	Validation and quantitation of an in vitro M-cell model. Biochemical and Biophysical Research Communications, 2002, 299, 377-383.	1.0	46
42	Challenges for the development of vaccines against Haemophilus influenzae and Neisseria meningitidis. Current Opinion in Immunology, 2002, 14, 553-557.	2.4	11
43	Vaccines and mucosal immunisation. Vaccine, 2001, 19, 2513-2515.	1.7	34
44	Programmed inflammatory processes induced by mucosal immunisation. Vaccine, 2001, 19, 2522-2526.	1.7	4
45	Mucosal immunity in the lung and upper airway. Vaccine, 2001, 19, 2527-2533.	1.7	45
46	Viral Co-Infection Does Not Reduce the Efficacy of Vaccination against Non-Typeable <i>Haemophilus influenzae</i> Middle Ear Infection in a Rat Model. Orl, 2001, 63, 96-101.	0.6	4
47	CD8+ T Cells Have an Essential Role in Pulmonary Clearance of Nontypeable Haemophilus influenzaefollowing Mucosal Immunization. Infection and Immunity, 2001, 69, 2636-2642.	1.0	17
48	Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine, 2000, 19, 348-357.	1.7	20
49	Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. Journal of Biotechnology, 2000, 83, 85-90.	1.9	15
50	Towards a Protein Vaccine for Nontypeable Haemophilus influenzae. Clinical Infectious Diseases, 1999, 28, 238-238.	2.9	8
51	Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Vaccine, 1999, 17, 1775-1781.	1.7	27
52	Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis. Vaccine, 1999, 18, 398-406.	1.7	28
53	Nontypeable Haemophilus influenzae: challenges in developing a vaccine. Journal of Biotechnology, 1999, 73, 103-108.	1.9	19
54	Characterization of the Gene Encoding a 26-Kilodalton Protein (OMP26) from Nontypeable <i>Haemophilus influenzae</i> and Immune Responses to the Recombinant Protein. Infection and Immunity, 1999, 67, 1935-1942.	1.0	27

#	Article	IF	CITATIONS
55	Characterization of the Gene Encoding a 26-Kilodalton Protein (OMP26) from Nontypeable Haemophilus influenzae and Immune Responses to the Recombinant Protein. Infection and Immunity, 1999, 67, 1935-1942.	1.0	9
56	Characteristics of the immunological response in the clearance of non-typeableHaemophilus influenzaefrom the lung. Immunology and Cell Biology, 1998, 76, 323-331.	1.0	13
57	Kinetics of inflammatory cytokines in the clearance of non-typeableHaemophilus influenzaefrom the lung. Immunology and Cell Biology, 1998, 76, 556-559.	1.0	13
58	Potential of a Novel Protein, OMP26, from Nontypeable <i>Haemophilus influenzae</i> To Enhance Pulmonary Clearance in a Rat Model. Infection and Immunity, 1998, 66, 2272-2278.	1.0	54
59	Nontypeable <i>Haemophilus influenzae</i> : Pathogenesis and Prevention. Microbiology and Molecular Biology Reviews, 1998, 62, 294-308.	2.9	207